Boston Scientific Corporation $BSX Shares Bought by Elevation Point Wealth Partners LLC

Elevation Point Wealth Partners LLC raised its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 429.8% in the first quarter, Holdings Channel.com reports. The fund owned 80,011 shares of the medical equipment provider’s stock after purchasing an additional 64,908 shares during the period. Elevation Point Wealth Partners LLC’s holdings in Boston Scientific were worth $5,021,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. FWL Investment Management LLC acquired a new position in Boston Scientific during the second quarter worth $26,000. Swiss RE Ltd. acquired a new stake in shares of Boston Scientific in the fourth quarter valued at $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at $26,000. Bangor Savings Bank raised its holdings in shares of Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 142 shares during the period. Finally, Board of the Pension Protection Fund purchased a new stake in shares of Boston Scientific in the 4th quarter valued at $29,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Boston Scientific news, Director David C. Habiger purchased 2,250 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the acquisition, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. This trade represents a 19.35% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig purchased 3,580 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was bought at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the purchase, the director directly owned 25,359 shares of the company’s stock, valued at $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have acquired 9,800 shares of company stock worth $554,012. 0.34% of the stock is currently owned by insiders.

Boston Scientific Price Performance

Boston Scientific stock opened at $45.09 on Friday. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The company has a fifty day simple moving average of $50.99 and a 200-day simple moving average of $69.43. The stock has a market cap of $67.01 billion, a P/E ratio of 18.86, a price-to-earnings-growth ratio of 0.86 and a beta of 0.58. Boston Scientific Corporation has a 12-month low of $42.25 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same quarter in the prior year, the company posted $0.75 earnings per share. Boston Scientific’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts expect that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has approved a stock buyback program on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analyst Weigh In

BSX has been the subject of a number of research analyst reports. Citigroup lowered their target price on Boston Scientific from $87.00 to $70.00 and set a “buy” rating for the company in a report on Thursday, May 28th. Bank of America reduced their price target on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. BTIG Research reissued a “buy” rating and issued a $65.00 price objective on shares of Boston Scientific in a research note on Tuesday, June 16th. Weiss Ratings cut shares of Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Finally, Wolfe Research lowered shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a report on Friday, May 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $83.36.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.